These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 30058236

  • 1. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
    Iwabuchi E, Miki Y, Kanai A, Miyashita M, Kijima G, Hirakawa H, Suzuki T, Ishida T, Sasano H.
    J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
    [Abstract] [Full Text] [Related]

  • 2. Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers.
    Tsang JY, Kwok YK, Chan KW, Ni YB, Chow WN, Lau KF, Shao MM, Chan SK, Tan PH, Tse GM.
    Breast Cancer Res Treat; 2013 Nov; 142(2):311-22. PubMed ID: 24186057
    [Abstract] [Full Text] [Related]

  • 3. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
    Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM, Speirs V.
    Clin Cancer Res; 2008 Jan 15; 14(2):405-11. PubMed ID: 18223215
    [Abstract] [Full Text] [Related]

  • 4. Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells.
    Iwabuchi E, Miki Y, Onodera Y, Shibahara Y, Takagi K, Suzuki T, Ishida T, Sasano H.
    Clin Exp Metastasis; 2019 Oct 15; 36(5):423-432. PubMed ID: 31222613
    [Abstract] [Full Text] [Related]

  • 5. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM.
    Breast Cancer Res; 2018 Nov 20; 20(1):140. PubMed ID: 30458861
    [Abstract] [Full Text] [Related]

  • 6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L.
    Oncotarget; 2015 Nov 10; 6(35):37269-80. PubMed ID: 26452030
    [Abstract] [Full Text] [Related]

  • 7. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y, Shimoda M, Hori A, Ohara A, Naoi Y, Ikeda JI, Kagara N, Tanei T, Shimomura A, Shimazu K, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2017 Nov 10; 166(1):55-68. PubMed ID: 28702892
    [Abstract] [Full Text] [Related]

  • 8. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R.
    Clin Cancer Res; 2017 Feb 01; 23(3):636-648. PubMed ID: 27698002
    [Abstract] [Full Text] [Related]

  • 9. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC, Li HY, Liang JL, Ger LP, Chang HT, Hsiao M, Calkins MJ, Cheng HC, Chuang JH, Lu PJ.
    Oncotarget; 2017 May 02; 8(18):29699-29710. PubMed ID: 27447863
    [Abstract] [Full Text] [Related]

  • 10. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.
    Breast Cancer Res Treat; 2012 Dec 02; 136(3):739-48. PubMed ID: 23117856
    [Abstract] [Full Text] [Related]

  • 11. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation.
    Chiang WF, Cheng TM, Chang CC, Pan SH, Changou CA, Chang TH, Lee KH, Wu SY, Chen YF, Chuang KH, Shieh DB, Chen YL, Tu CC, Tsui WL, Wu MH.
    Oncogene; 2018 Jan 04; 37(1):116-127. PubMed ID: 28892050
    [Abstract] [Full Text] [Related]

  • 12. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I, Tuxen MK, Nielsen DL.
    Cancer Treat Rev; 2014 Mar 04; 40(2):259-70. PubMed ID: 24080156
    [Abstract] [Full Text] [Related]

  • 13. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
    Wu D, Jia HY, Wei N, Li SJ.
    Biochem Biophys Res Commun; 2020 Dec 10; 533(3):533-539. PubMed ID: 32988584
    [Abstract] [Full Text] [Related]

  • 14. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
    Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
    Oncotarget; 2016 Dec 20; 7(51):84860-84871. PubMed ID: 27768588
    [Abstract] [Full Text] [Related]

  • 15. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
    Horii R, Nitta H, Nojima M, Maruyama R, Ueno T, Ito Y, Ohno S, Banks P, Kanda H, Akiyama F.
    Virchows Arch; 2021 Jul 20; 479(1):13-21. PubMed ID: 33496805
    [Abstract] [Full Text] [Related]

  • 16. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.
    Oncotarget; 2016 Aug 30; 7(35):56295-56308. PubMed ID: 27462779
    [Abstract] [Full Text] [Related]

  • 17. Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.
    Abduyev Z, Altundag K.
    J BUON; 2019 Aug 30; 24(5):2208. PubMed ID: 31786900
    [No Abstract] [Full Text] [Related]

  • 18. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
    Chung WP, Huang WL, Liao WA, Huang WL, Liu YY, Su WC.
    Cancer Med; 2021 Apr 30; 10(7):2370-2379. PubMed ID: 33665980
    [Abstract] [Full Text] [Related]

  • 19. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
    Dong H, Wang W, Chen R, Zhang Y, Zou K, Ye M, He X, Zhang F, Han J.
    Int J Oncol; 2018 Sep 30; 53(3):1013-1026. PubMed ID: 30015837
    [Abstract] [Full Text] [Related]

  • 20. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z.
    Cancer Lett; 2018 Aug 28; 430():47-56. PubMed ID: 29746929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.